News brief
A major Cochrane review has raised concerns about the effectiveness of drugs aimed at removing amyloid beta proteins from the brain, a strategy once seen as viable for treating Alzheimer’s. Analyzing data from over 20,000 participants, the review found these drugs do not significantly slow cognitive decline and may increase the risk of brain swelling and bleeding, often without noticeable symptoms. These findings suggest a need to explore different biological pathways for effective Alzheimer’s treatments.
Key points
- Drugs targeting amyloid proteins have little effect on Alzheimer’s progression.
- Higher risks of brain swelling and bleeding are associated with these drugs.
- Research into alternative treatment pathways is encouraged.
Questionable Benefits in Trials
The Cochrane review looked at data from 17 clinical trials with 20,342 participants who had mild cognitive impairment or early-stage Alzheimer’s dementia. Despite early optimism, the effect of anti-amyloid drugs on memory decline and dementia severity was minimal. The changes observed were not enough to be considered clinically meaningful, challenging the belief that clearing amyloid could slow the disease’s progression.
Concerns Over Safety
Beyond their limited effectiveness, the review pointed out safety issues with amyloid-targeting drugs. Participants on these treatments were more likely to experience brain swelling and bleeding. Often, these side effects were only detectable through brain scans, raising questions about their long-term impact. The inconsistency in how symptoms were reported across studies adds another layer of complexity to assessing these risks.
Shifting Research Focus
With the lack of significant clinical benefits and potential risks, researchers are calling for a move away from amyloid-targeting strategies. The review’s authors recommend investigating other biological pathways involved in Alzheimer’s disease. This shift is already happening, with many studies exploring alternative approaches that could lead to more effective treatments.
Discover more from Neurospan
Subscribe to get the latest posts sent to your email.
